Marshall & Sterling Wealth Advisors Inc. Compass Therapeutics, Inc. Transaction History
Marshall & Sterling Wealth Advisors Inc.
- $145 Billion
- Q4 2024
A detailed history of Marshall & Sterling Wealth Advisors Inc. transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Marshall & Sterling Wealth Advisors Inc. holds 200 shares of CMPX stock, worth $676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200Holding current value
$676% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CMPX
# of Institutions
89Shares Held
93.2MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA22.4MShares$75.6 Million0.88% of portfolio
-
Blackstone Inc New York, NY10MShares$33.9 Million0.07% of portfolio
-
Bio Impact Capital LLC Cambridge, MA8.57MShares$29 Million1.86% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$22.4 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.99MShares$20.3 Million0.02% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $342M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...